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1 Introduction 
Candida species colonize the gastrointestinal and repro-
ductive tract and skin of most individuals and are among 
the most common causes of hospital-acquired bloodstream 
infections in the United States.1,2 In healthy persons, car-
riage of Candida albicans is estimated at 30%-60%. 3 How-
ever, Candida species can also act as opportunistic patho-
gens that are capable of infecting a broad range of body 
sites, especially when host resistance mechanisms are com-
promised. Candidemia, when Candida gains access to the 
bloodstream, is a life-threatening condition, with mortality 
rate estimates of nearly 50%,4 especially in immunocom-
promised patients. 
Solid organ transplant (SOT) recipients present a unique 
combination of risk factors that may predispose them to 
candidemia, including prolonged administration of immu-
nosuppressive therapies, repeated courses of broad-spec-
trum antibiotics, hemodialysis, various surgical procedures 
and presence of central venous catheters.5,6 SBT recipients 
evince a higher incidence of allograft rejection than other 
SOT recipients, due to the high immunogenicity of the bowel, 
and therefore require more potent immunosuppression ther-
apy.7 During episodes of allograft rejection or breach of the 
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Abstract 
Small bowel transplantation (SBT) can be a life-saving medical procedure. However, these recipients ex-
perience high risk of bloodstream infections caused by Candida. This research aims to characterize the 
SBT recipient gut microbiota over time following transplantation and investigate the epidemiology of 
candidemia in seven pediatric patients. Candida species from the recipients’ ileum and bloodstream were 
identified by internal transcribed spacer sequence and distinguished to strain by multilocus sequence 
typing and randomly amplified polymorphic DNA. Antifungal susceptibility of bloodstream isolates was 
determined against nine antifungals. Twenty-two ileostomy samples harbored at least one Candida spe-
cies. Fungemia were caused by Candida parapsilosis, Candida albicans, Candida glabrata, Candida or-
thopsilosis and Candida pelliculosa. All but three bloodstream isolates showed susceptibility to all the 
antifungals tested. One C. glabrata isolate showed multidrug resistance to itraconazole, amphotericin B 
and posaconazole and intermediate resistance to caspofungin. Results are congruent with both endoge-
nous (C. albicans, C. glabrata) and exogenous (C. parapsilosis) infections; results also suggest two patients 
were infected by the same strain of C. parapsilosis. Continuing to work towards a better understanding of 
sources of infection—particularly the exogenous sources—would lead to targeted prevention strategies. 
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gastrointestinal tract during surgery, breakdown of the gut 
epithelial barrier occurs, which can lead to the translocation 
of enteric organisms from the recipient or donor bowel into 
the bloodstream or peritoneum. 
Small bowel transplantation is considered a last-resort 
treatment option for pediatric patients with extreme short 
bowel syndrome or those suffering life-threatening compli-
cations from parenteral nutrition. Bloodstream infections are 
common complications following intestinal transplant and 
represent a major cause of morbidity and mortality among 
SBT recipients, with up to 70% of pediatric SBT recipients 
developing bloodstream infections.8 In particular, pediat-
ric SBT recipients experience an increased incidence of can-
didemia, with up to 25% of recipients developing candi-
demia—the most common fungal bloodstream infection in 
this population.9 
Strains implicated in candidemia may be of endogenous or 
exogenous origin.10 The donor and remnant recipient bowel 
may each harbor commensal fungi,6 and donor organs may 
additionally become infected during hospitalization of the do-
nor or during procurement and preservation of the organ.10,11 
There is increasing evidence for Candida infections originating 
from the hospital environment and personnel, contaminated 
implanted medical devices, or from the skin.12-14 The ability of 
Candida to produce biofilms on catheter instruments is a com-
mon source of candidemia episodes, as these give the yeast 
direct access into the bloodstream upon insertion.15 
Antifungal prophylaxis is commonly administered in the 
first weeks after surgery in SBT recipients. However, extensive 
use of antifungal prophylaxis can select for resistant Candida 
strains. For instance the recent clinical emergence of azole-
resistant species (Candida glabrata and Candida krusei) is 
likely due to widespread use of fluconazole and other an-
tifungal agents.16 In addition, an overall shift towards non-
C. albicans species commonly associated with fungemia has 
been observed,17 possibly related to the extensive use of an-
tifungal prophylaxis. 
In the present work, we defined the gut mycobiota of SBT 
recipients and genotyped ileum and bloodstream Candida iso-
lates in attempt to infer the source of infection, and determine 
the distribution of isolates within and between patients. Iso-
lates were also assessed for antifungal susceptibility. Overall, 
the data obtained in this study will contribute to the knowl-
edge base of Candida epidemiology and infections acquired 
by SBT recipients and will also help design future studies. 
2  Materials and methods 
Seven pediatric short bowel syndrome patients who under-
went SBT and later developed candidemia at the University 
of Nebraska Medical Center (UNMC) were included in this 
study. The patient cohort comprised three females and four 
males with a mean age of 23.1 months (median: 20 months; 
range: 16-37 months). UNMC is a premier facility for SBT, 
conducting approximately 20 transplants per year. Ileostomy 
and blood samples (Table 1) were collected from recipients 
under UNMC Institutional Review Board protocol #417-02, 
and informed consent was received from the caregivers of all 
patients. Candidemia was diagnosed on the basis of at least 
one sample isolated in pure culture from the blood, which 
was then identified by the API 20 C test (BioMérieux, Marcy 
l’Etoile, France). Multiple ileostomy samples were collected 
post-transplant during hospitalization from each patient and 
stored at −80°C until processing. 
To obtain pure culture isolates from ileostomy samples, 
approximately 250 μL of ileal effluent was grown at 37°C in 
liquid media (yeast nitrogen broth [YNB; 6.7 g/L yeast nitro-
gen base, 10 g/L glucose, 0.76 g/L l-asparagine, 50 mg/L 
chloramphenicol, 20 mg/L gentamicin sulfate], and yeast ex-
tract peptone dextrose broth [YPD; 10 g/L yeast extract, 20 
g/L peptone, 20 g/L glucose, 50 mg/L chloramphenicol, pH 
5.6]) to restore cells that may have been damaged by up to 
10 years storage at −80°C with possible exposure to freeze-
thaw cycles and to increase the volume available for plating. 
Volumes of 100 μL were plated after 24, 48 and 72 hours 
on YPD agar (supplemented with 50 mg/L chlorampheni-
col), CHROMagar Candida (Paris, France), potato dextrose 
agar (PDA, Oxoid; supplemented with 50 mg/L chloramphen-
icol) and dichloran rose bengal chloramphenicol agar (DRBC; 
10 g/L glucose, 5 g/L peptone, 1 g/L monopotassium phos-
phate, 0.5 g/L magnesium sulfate, rose bengal 0.025 g/L, di-
chloran 0.002 g/L chloramphenicol 0.10 g/L). Multiple liquid 
and solid media were used to maximize the chances of isolat-
ing fungi. Plates were incubated at 37°C and monitored daily 
for 2 weeks. Multiple colonies from each plate were further 
isolated on the basis of color and morphology. 
DNA was extracted from yeast cultures following the 
methods of Harju et al.18 DNA from each ileostomy sam-
ple and pure culture isolate was selectively amplified by PCR 
using fungal-specific primers ITS1-F and ITS4 as described 
in Suhr et al.19 To survey the gut mycobiota, DNA was ex-
tracted directly from ileostomy effluent following the pro-
tocol of Oh et al.20 
PCR products from ileostomy effluent were cloned using 
the pGEM®-T Easy Vector System Kit (Promega, Lyon, France) 
following the manufacturer’s instructions. For each sample, 
25 colonies negative for β-galactosidase activity were evalu-
ated and those with distinct EcoR1 patterns were sequenced 
on an ABI 3730xl platform at Michigan State University’s Re-
search Technology Support Facility (East Lansing, MI, USA). 
Fungal sequences were identified by sequence homology us-
ing nucleotide BLAST against the UNITE curated fungal ITS 
sequence database21 and the curated FUNCBS database, as 
accessed through the Centraalbureau voor Schimmelcultures 
(http://www.cbs.knaw.nl/Collections/BioloMICSSequences.
aspx?file=all ; accessed September 2014). Sequences were 
deposited as GenBank accessions #KU987836-KU987907. 
All C. albicans and C. glabrata ileostomy and bloodstream 
isolates were typed by MLST as described previously.22,23 Af-
ter amplification of each fragment, PCR products were pu-
rified using the Wizard SV Gel and PCR Clean-up Kit (Pro-
mega, Madison, WI, USA). Subsequently, amplicons were 
sequenced in both directions using the same primers used 
for PCR. Sequences were aligned and assembled using 
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ClustalW implemented in BioEdit Sequence Alignment Ed-
itor version 7.3.2. For C. albicans, heterozygosities were as-
sessed by visual inspection of the chromatograms and des-
ignated using IUPAC nomenclature. Sequences were entered 
into the respective MLST database (http://pubmlst.org/cal-
bicans/  & http://cglabrata.mlst.net/), and assigned an allele 
profile for each locus which produced a sequence type (ST) 
based on the entire allelic combination  
Table 1. Outline of patients, sample collection, species identification, RAPD and MLST genotypes
 Age at
 transplant   Days Ileal  Ileal fungi Blood RAPD MLST
Patient (mo) Sex  Samplea posttransplant Candidab (non-Candida) isolate genotypec genotype
P32  28  F  32_I_1  390  CA  Acr, EN, PR
   32_B_1  400    CPd  G  n/a
P33  37  F  33_I_1  532  CA, CK  PR
   33_I_2  579  CAd, CK    A  2854
   33_B_1  587    CAd  A  2854
   33_I_3  755  CA, CG, CKd, CTd
P39  23  M  39_I_1  64  CGd    D  3
   39_B_1  187    CGd  D  3
   39_I_2  201  CGd    D  3
P47  20  F  47_I_1  12   EN, PR
   47_I_2  23  CP  Deb, PR, Tri
   47_I_3  27  CGd, CP    E  2
   47_B_1  29    CPd  H  n/a
   47_I_4  30  CGd, CPd  PR   CG-E, CP-G CG-2, CP-n/a
   47_I_5  34  CGd, CP  PR   E  2
   47_B_2  35    CPd  H  n/a
   47_I_6  41  CG
   47_I_7  48  CGd    E  2
   47_I_8  56  CG
   47_I_9  61  CGd, CP    E  2
P62  16  M  62_I_1  53   PR
   62_I_2  61  CA  Fus, PR
   62_B_1  69    WAd  n/a  n/a
   62_I_3  72  CA, CT  Deb, Fus, PF, PR
   62_I_4  103  CA, CPd    G  n/a
   62_I_5  138  CA PR
P74  20  M  74_I_1  254  CA  PR
   74_I_2  274   PR
   74_B_1  282    CPd  G  n/a
   74_I_3  357  CA, CL
   74_I_4  381  CA  EN, PR
   74_B_2  392    CAd  B  2855
   74_I_5  400   AP
   74_I_6  402   SC
P88  18  M  88_B_1  188    COd
   88_I_1  189   PR
   88_I_2  201  CK  EN, PR, SC
a. Sample name given as patient number_ileostomy (I) or bloodstream (B)_sample number.
b. CA, Candida albicans; CG, C. glabrata; CK, C. krusei; CL, C. lusitaniae; CO, C. orthopsilosis; CP, C. parapsilosis; CT, C. tropicalis; Acr, Acremonium; 
Deb, Debaryomyces; Fus, Fusarium; Tri, Trichoderma; AP, Aureobasidium pullulans; EN, Epicoccum nigrum; PF, Pichia fermentens; PR, Penicillium cf. 
roqueforti; SC, Saccharomyces cerevisiae; WA, Wickerhamomyces anomalus.
c. RAPD and MLST genotypes are given for samples in pure cultured only, and are described in the text. Candida parapsilosis lacks an MLST, and W. 
anomalus lacks MLST and RAPD, systems.
d. Obtained in culture.
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Candida albicans, C. glabrata and Candida parapsilosis 
isolates were also typed by RAPD using the primer Oligo 
2 (5′-TCACGATGCA- 3′) as described previously.24 Candida 
parapsilosis isolates were further typed with the primer OPE-
04 (5′-GTGACATG-3′). 25 Amplification reactions were as de-
scribed above for PCR except 10 ng of DNA was used. Am-
plicons were separated in a 1.5% agarose gel for 90 minutes 
and visualized. 
Antifungal susceptibility was assessed using the Sensititre 
YeastOne YO-9 plate (TREK Diagnostic Systems, Cleveland, 
OH, USA), which provides antifungal susceptibility testing 
and minimum inhibitory concentration (MIC) determina-
tion against nine antifungals (see Table 2, below), follow-
ing the manufacturer’s instructions. Guidelines for break-
point interpretations for amphotericin B were determined 
from CLSI M27-A26; for anidulafungin, caspofungin, flucon-
azole, micafungin and voriconazole from CLSI M27-S4;27 for 
5-flucytosine and itraconazole from CLSI M27-S3,28 and for 
posaconazole from the European Committee on Antimicro-
bial Susceptibility Testing.29 
3  Results 
The ileal effluent of SBT recipients harbored several fungal spe-
cies (Table 1). Candida albicans was the predominant species, 
detected in the ileum of four patients (57%) and 11 out of 28 
ileostomy samples (40%). All ileum samples tested contained 
detectable fungi, and the species detected per sample ranged 
from 1 to 6. P33 harbored four Candida species in a single ileal 
sample. Other, non-Candida fungi were also detected in 60% 
of ileal samples, with Penicillium roqueforti and/or allied spe-
cies (Penicillium roqueforti, Penicillium carneum and Penicil-
lium paneum cannot reliably be distinguished on the basis of 
ITS sequence) detected in samples for all patients. 
Species isolated from each blood culture are shown in Ta-
ble 1. All bloodstream infections were caused by Candida. 
Candida parapsilosis was the predominant species isolated 
from the bloodstream (three patients). Candida albicans was 
the second most-isolated species from the bloodstream, in 
two patients, whereas C. glabrata, C. orthopsilosis and C. pel-
liculosa (=C. beverwijkiae Wickerhamomyces anomalus) were 
each isolated from one patient. P74 sustained two distinct 
bloodstream infections, from C. parapsilosis in July 2006 and 
from C. albicans in November of 2006. 
All C. albicans (n = 3) and C. glabrata (n = 8) isolated in 
culture from the ileum and bloodstream were subjected to 
MLST. Twelve alleles were identified among the seven loci of 
C. albicans isolates, including two new alleles, which gener-
ated a new, unique diploid sequence type (Table S1). Four-
teen polymorphic nucleotide sites were found between the 
two C. albicans sequence types. Both C. albicans sequence 
types detected in this study (ST 2854 & ST 2855) are novel 
isolates and have been deposited in the MLST database. In 
addition, two sequence types (ST 2 & ST 3), consisting of 
12 alleles and 23 variable nucleotide sites, were identified 
among the six loci of C. glabrata isolates (Table S1). 
For P33, ileostomy and blood C. albicans isolates yielded 
one sequence type (ST 2854). Candida albicans causing 
bloodstream infection in P74 was ST 2855, distinct from 
P33. Candida glabrata ileostomy and bloodstream isolates 
from P39 shared ST 3. P47, who developed candidemia by C. 
parapsilosis, had gastrointestinal colonization by C. glabrata. 
However, the C. glabrata isolated from this individual was ST 
2, which was a distinct genotype from P39. In both species 
for which MLST was possible, sequence type was consistent 
within a patient over time, but differed between patients. 
RAPD fingerprinting with primer Oligo 2 was performed 
on all cultured Candida isolates that were detected more than 
once (see Table 1; Figures S2-S4). Four C. albicans isolates gen-
erated three distinct RAPD profiles. Candida albicans isolates 
recovered from the ileostomy and bloodstream of P33 had the 
same RAPD profile A. The bloodstream isolate from P74 gave a 
distinct RAPD profile B (C. albicans was detected in ileostomy 
samples from P74 but could not be cultured). The common 
laboratory strain C. albicans SC5314 also gave a distinct pat-
tern C. Nine C. glabrata isolates generated three distinct RAPD 
profiles. Candida glabrata isolates obtained from the ileostomy 
and bloodstream of P39 had the same RAPD profile D. Can-
dida glabrata ileostomy isolates from five consecutive ileos-
tomy samples over a 1 month period in P47 generated RAPD 
profile E, whereas control strain C. glabrata NRRL Y-65 gave a 
distinct RAPD pattern F. The RAPD results obtained from C. al-
bicans and C. glabrata isolates are congruent with strain typ-
ing data by MLST (Table 1). No RAPD patterns for C. albicans 
or C. glabrata were shared across individuals. 
Seven C. parapsilosis isolates generated two distinct RAPD 
profiles. Candida parapsilosis isolates from P47 showed dis-
tinct RAPD patterns between the ileum and bloodstream. The 
two C. parapsilosis blood culture isolates were collected from 
this patient before and after the ileostomy sample was col-
lected. Both blood cultures generated the same RAPD pattern 
H. However, the ileostomy isolate showed RAPD pattern G. 
The two ileostomy samples prior to the first bloodstream col-
lection harbored C. parapsilosis, but viable organisms could 
not be cultured; therefore, RAPD could not be used to iden-
tify the C. parapsilosis to strain. Three C. parapsilosis isolates, 
collected from the ileum of P62 and the blood of P32 and 
P74, gave the same RAPD pattern G. Control C. parapsilosis 
232, isolated from cheese, also had RAPD pattern G. Since 
a C. parapsilosis MLST scheme does not exist, primer OPE-
04 was also used for RAPD to confirm results obtained by 
primer Oligo 2. Primer OPE-04 also yielded two distinct pat-
terns among the seven isolates, which agreed with the results 
from Oligo 2 RAPD (Figure S5). 
The chronological carriage of Candida strains is shown in 
Figure 1. At two points, samples were collected from multiple 
patients during the same time period. In both cases, patients 
carried distinct strains from one another. Candida parapsilosis 
isolates of RAPD profile G were detected consistently over time 
in four patients. Isolates of all other MLST and RAPD profiles 
were each restricted to a single patient in the tested samples. 
No one genotype dominated the patient population. 
The antifungal susceptibilities and MICs for the yeast iso-
lates against nine antifungals are shown in Table 2. Candida 
glabrata isolate 39_B_1 was reported as susceptible dose-de-
pendent to fluconazole (which was administered in a level to 
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patient considered susceptible), intermediate to caspofungin, 
and resistant to amphotericin B, itrazonazole and posacon-
azole. Candida parapsilosis isolates 47_B_1 and 47_B_2 were 
determined to be resistant to amphotericin B. Candida albi-
cans, C. orthopsilosis and C. pelliculosa isolates were uniformly 
susceptible or susceptible dose dependent (74_B_2 for flucon-
azole) to all antifungals. In addition, we tested one ileal isolate 
of C. krusei (from 33_I_3; not shown). This isolate was resistant 
to fluconazole, showed an intermediate response to 5-flucy-
tosine, and was susceptible dose-dependent to itraconazole. 
Isolates showed a wide range of MICs to fluconazole (0.5-32 
μg/mL), as well as micafungin (<0.008-2 μg/mL), anidulafun-
gin (0.015-2 μg/mL) and caspofungin (0.015-2 μg/mL), and a 
narrow range for 5-flucytosine (<0.06-0.25 μg/mL). 
4  Discussion 
This study describes SBT recipients who developed funge-
mia post-transplant at the UNMC from 2004 to 2007. We 
employed a variety of techniques to identify and characterize 
Candida isolates colonizing and infecting SBT recipients. This 
is the first study characterizing the fungal intestinal microbi-
ota of SBT recipients. Comprehensive surveys of gut fungi, us-
ing next-generation sequencing methods, may report dozens 
of species or OTUs (operational taxonomic units) from a sin-
gle fecal sample30; however, the majority of these are rarely 
detected environmental or dietary fungi that do not appear 
to colonize the gastrointestinal tract.31 The fungi we detected 
from ileostomy samples in this study are largely those spe-
cies that do have a well-established association with and role 
in the gut, especially Candida species. 
Prior to 1990, the predominant species causing Candida 
infections was C. albicans.32 In recent years infections caused 
by non-albicans species have increased in clinical impor-
tance.17 Bloodstream infections in our study were most fre-
quently caused by C. parapsilosis (four cases), whereas C. 
albicans was isolated in only two infections. Only P47 experi-
enced candidemia shortly after transplant (at 29 and 35 days, 
with C. parapsilosis), accordingly, this is the only patient for 
whom the 2 week postoperative antifungal prophylaxis with 
fluconazole was anticipated to influence species isolated or 
susceptibility. One infection each was caused by C. glabrata, 
C. orthopsilosis and C. pelliculosa. 
Candida pelliculosa is widespread in the environment and 
in food, and is an opportunistic human and animal patho-
gen. This yeast transiently colonizes the oropharyngeal and 
gastrointestinal tract of humans and it has been implicated 
in outbreaks in neonatal and pediatric intensive care units.33 
Candida pelliculosa was not identified in the intestine of P62 
from whom it was isolated from the blood. Therefore, it is 
possible that this patient acquired this species from an ex-
ogenous source, as suspected in previous cases.34 
We detected previous digestive tract colonization with 
Candida in six of the patients with candidemia. Our findings 
suggest that at least two bloodstream infections (in P33 and 
P39) originated from Candida colonizing the small bowel, al-
though complete exclusion of environmental exposure dur-
ing hospitalization is not possible at this time. Closely re-
lated isolates in the intestine and blood have been reported 
in other studies.35,36 Gastrointestinal colonization is an impor-
tant source of candidemia, although only a few studies using 
molecular typing methods have been reported and sample 
numbers are small.14 Many studies only report an associa-
tion between anatomic site of Candida colonization as a risk 
factor for subsequent candidemia and invasive candidiasis in 
hospitalized and critically ill patients.37,38 However, it is plau-
sible that patients in our study would be infected by endog-
enous Candida due to the invasive nature of this procedure. 
P47 had different strains of C. parapsilosis colonizing the 
intestine and infecting the bloodstream, suggesting candi-
demia derived from a distinct source. Candida parapsilo-
sis has been reported in the human oral microbiota so en-
dogenous infection remains a possibility. Other possibilities 
include mutation within the patient and increase in preva-
lence of a previously undetectable isolate. Nucleotide se-
quence variation among serial isolates or as separate clones 
from individual patients is a known phenomenon for strains 
of C. albicans.39 The majority of documented C. parapsilosis 
Figure 1. Chronological outline of patient sample collection. The MLST sequence types and RAPD profiles are indicated for each patient 
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infections are of exogenous origin; endogenous infections 
are rarely seen.36 Candida parapsilosis is the most common 
fungus recovered from the hands and studies have impli-
cated health care workers’ hands as the source of nosoco-
mial candidaemia.40 Another possible route of C. parapsilo-
sis transmission could be contaminated parenteral nutrition 
and intravascular devices.41 Candida parapsilosis was not de-
tected in ileostomy samples from P32 and P74, who devel-
oped bloodstream infection with C. parapsilosis. These two 
individuals could represent further cases of exogenous ac-
quisition. In addition to P88, who had no gastrointestinal col-
onization with the fungus isolated from the bloodstream, C. 
orthopsilosis, may have acquired candidemia exogenously. 
P74 was co-infected by two Candida species. Candida 
parapsilosis was the first organism recovered from the blood, 
but this was not detected in ileostomy samples prior to infec-
tion. Candida albicans was present in three ileostomy samples 
prior to C. albicans detection in the blood. The possibility ex-
ists that P74 was infected exogenously by C. parapsilosis and 
endogenously by the patient’s own intestinal C. albicans. The 
inability to culture C. albicans from the patient’s ileum pre-
cluded strain typing and thus confirmation of a possible en-
dogenous source. 
Studies have documented the ability of Candida isolates to 
persist in hospital settings and cause temporally associated 
infections.42,43 In our study, temporal analysis revealed multi-
ple species were responsible for causing bloodstream infec-
tions during the study period. At two different time points, 
samples collected from two patients overlapped, but the pa-
tients did not carry the same genotype. However, the same 
C. parapsilosis genotype G in four patients was documented 
at multiple time points. Therefore, there is potential evidence 
that this C. parapsilosis strain had a common source. How-
ever, environmental sampling would be necessary to confirm 
or rule out any exogenous source. 
Methods used to strain-type Candida species have greatly 
advanced our knowledge of fungal epidemiology and MLST 
has been shown to be more discriminating than RAPD for 
C. albicans.44 In our study, MLST detected distinct sequence 
types between, but not within, patients. This suggests inde-
pendent, endogenous acquisition of C. albicans candidemia, 
but would need to be confirmed by full genome sequencing. 
RAPD patterns yielded the same conclusions as MLST for C. 
albicans and C. glabrata isolates. RAPD fingerprints gener-
ated by two independent primers gave the same results for 
C. parapsilosis isolates. Other RAPD primers may possibly fur-
ther differentiate between our isolates; conversely, genetic 
variation in C. parapsilosis may be minimal. Other methods 
such as microsatellite markers may be more discriminatory 
for epidemiological investigations of C. parapsilosis,45 but ul-
timately future work will have to encompass full genome se-
quence of well-documented, larger collections. 
There is increasing concern regarding antifungal resis-
tance in Candida, especially C. parapsilosis. In our study, two 
C. parapsilosis isolates from the same patient showed resis-
tance to amphotericin B. In addition, the one isolate of C. gla-
brata also showed resistance to amphotericin B using the in 
vitro microplate susceptibility testing method. Although re-
sistance of Candida species to amphotericin B is rare, the fre-
quency of resistance to amphotericin B has been shown to be 
highest with C. parapsilosis (2.5%) followed by C. krusei (2.0%) 
and C. glabrata (0.8%).46 Interestingly also, the formation of 
biofilms in C. parapsilosis did lead to a significant (P = .0004) 
lowering of activity for amphotericin B from 100% suscepti-
ble to 32.1% susceptible in this species.47 However, there are 
no standardized methods available to perform and interpret 
in vitro amphotericin B susceptibility testing.26 Candida albi-
cans isolates from this study were susceptible to all antifun-
gal agents. The C. glabrata strain causing candidemia in addi-
tion to amphotericin B was also resistant to itraconazole and 
posaconazole, intermediate to caspofungin and susceptible 
dose-dependent to fluconazole. This strain was also detected 
in the patient’s ileal fluid 4 months prior to infection. One other 
patient harbored C. glabrata in the ileum, but was only infected 
by C. parapsilosis. The one C. krusei isolate we obtained in cul-
ture showed some level of drug resistance, notably to flucon-
azole; however, no C. krusei strain in this study was implicated 
in candidemia. All patients were exposed to fluconazole pro-
phylaxis in the immediate perioperative period. 
One limitation of this study was the inability to culture vi-
able organisms from several ileostomy samples. Thus, while 
we know an ileostomy sample harbored a specific species, 
intestinal origin could not be confirmed due to the inabil-
ity to strain-type. Techniques to strain-type species in mixed 
matrices need to be developed to avoid requiring pure cul-
tures of isolates. Another limitation was the inability to de-
termine whether ileal Candida originated in the donor or re-
cipient bowel. Donor-derived Candida infections have been 
documented in kidney transplant recipients.48 To date, no 
efforts have been made to identify Candida species and/or 
strains from the donor small bowel, or from other sources of 
recipient microbiota, to investigate the origin of candidemia 
in SBT recipients. 
These findings highlight the possibility of hospitalized SBT 
patients acquiring candidemia both endogenously and exog-
enously, although the exact route of infection in these trans-
plant patients is not clear. Knowing the source of Candida im-
plicated in infection (recipient, donor or hospital acquired) 
will inform pretransplant interventions and treatments to im-
prove outcomes for SBT patients. Future efforts should in-
clude collection and culturing of donor and recipient samples 
(including oral, colon and skin microbiota) prior to transplant, 
as well as continuing ileostomy sample collection through-
out hospitalization. This would highlight the role (if any) of 
the donor microbiota and may direct prevention efforts. Tar-
geted interventions could reduce exogenous and endog-
enous infections, and environmental sampling may reveal 
sources of infection and solutions. Reducing endogenous re-
cipient-derived infection by means of existing prophylactics 
will be more difficult and will require innovative interventions. 
Acknowledgments — This research was funded in part by a Maude 
Hammond Fling Faculty Research Fellowship Award from the Univer-
sity of Nebraska-Lincoln Research Council to Heather Hallen-Adams. 
8 Suhr et  al .  in Mycoses  2017 
The authors declare that they have no conflict of interest. 
References 
1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Ed-
mond MB. Nosocomial bloodstream infections in US hospitals: 
analysis of 24,179 cases from a prospective nationwide surveil-
lance study. Clin Infect Dis. 2004;39:309–317. 
2. Magill SS, Edwards JR, Bamberg W et al. Multistate point-preva-
lence survey of health care-associated infections. N Engl J Med. 
2014;370:1198–1208. 
3. Moran G, Coleman D, Sullivan D. An introduction to the med-
ically important Candida species. In: Calderon RA, Clancy CJ, 
eds. Candida and Candidiasis, 2nd edn. Washington, DC: ASM 
Press; 2012:11–25. 
4. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mor-
tality of nosocomial candidemia, revisited. Clin Infect Dis. 
2003;37:1172–1177. 
5. Florescu DF, Qiu F, Mercer DF, Langnas AN, Shaf LR. Risk factors 
for systemic Candida infections in pediatric small bowel trans-
plant recipients. Pediatr Infect Dis J. 2012;31:120–123. 
6. Shoham S, Marr KA. Invasive fungal infections in solid organ trans-
plant recipients. Future Microbiol. 2012;7:639–655. 
7. Pirenne J, Kawai M. Intestinal transplantation: evolution in im-
munosuppression protocols. Curr Opin Organ Transplant. 
2009;14:250–255. 
8. Florescu DF, Qiu F, Langnas AN et al. Bloodstream infections dur-
ing the first year after pediatric small bowel transplantation. Pe-
diatr Infect Dis J. 2012;31:700–704. 
9. Florescu DF, Islam KM, Grant W et al. Incidence and outcome of 
fungal infections in pediatric small bowel transplant recipients. 
Transpl Infect Dis. 2010;12:497–504. 
10. Grossi PA. Clinical aspects of invasive candidiasis in solid organ 
transplant recipients. Drugs. 2009;69(Suppl 1):15–20. 
11. Ison MG, Nalesnik MA. An update on donor-derived dis-
ease transmission in organ transplantation. Am J Transplant. 
2011;11:1123–1130. 
12. Huang YC, Lin TY, Leu HS, Wu JL, Chang HY. Yeast carriage on 
hands of hospital personnel working in intensive care units. J 
Hosp Infect. 1998;39:47–51. 
13. Huang YC, Lin TY, Leu HS, Peng HL, Wu JH, Chang HY. Out-
break of Candida parapsilosis fungemia in neonatal intensive 
care units: clinical implication and genotyping analysis. Infec-
tion. 1999;27:97–102. 
14. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or 
gut? Clin Infect Dis. 2001;33:1959–1967. 
15. Levin AS, Costa SF, Muss NS et al. Candida parapsilosis funge-
mia associated with implantable and semi-implantable central 
venous catheters and the hands of healthcare workers. Diagn 
Microbiol Infect Dis. 1998;30:243–249. 
16. Singh N. Antifungal prophylaxis for solid organ transplant re-
cipients: seeking clarity amidst controversy. Clin Infect Dis. 
2000;31:545–553. 
17. Sobel JD. The emergence of non-albicans Candida species as 
causes of invasive candidiasis and candidemia. Curr Infect Dis 
Rep. 2006;8:427–433. 
18. Harju S, Fedosyuk H, Peterson KR. Rapid isolation of yeast ge-
nomic DNA: Bust n’ Grab. BMC Biotechnol. 2004;4:8. 
19. Suhr MJ, Banjara N, Hallen-Adams HE. Sequence-based meth-
ods for detecting and evaluating the human gut mycobiome. 
Lett Appl Microbiol. 2016;62:209–215. 
20. Oh PL, Martínez I, Sun Y, Walter J, Peterson DA, Mercer DF. 
Characterization of the ileal microbiota in rejecting and nonre-
jecting recipients of small bowel transplants. Am J Transplant. 
2012;12:753–762. 
21. Kõljalg U, Nilsson RH, Abarenkov K et al. Towards a unified par-
adigm for sequence-based identification of fungi. Mol Ecol. 
2013;22:5271–5277. 
22. Bougnoux ME, Tavanti A, Bouchier C et al. Collaborative consen-
sus for optimized multilocus sequence typing of Candida albi-
cans. J Clin Microbiol. 2003;41:5265–5266. 
23. Dodgson AR, Pujol C, Denning DW, Soll DR, Fox AJ. Multilocus 
sequence typing of Candida glabrata reveals geographically en-
riched clades. J Clin Microbiol. 2003;41:5709–5717. 
24. Binelli CA, Moretti ML, Assis RS et al. Investigation of the possi-
ble association between nosocomial candiduria and candidemia. 
Clin Microbiol Infect. 2006;12:538–543. 
25. Bautista-Muñoz C, Bolda XM, Villa-Tanaca L, Hernández-Rodrí-
guez C. Identification of Candida spp. by randomly amplified 
polymorphic DNA analysis and differentiation between Candida 
albicans and Candida dubliniensis by direct PCR methods. J Clin 
Microbiol. 2003;41:414–420. 
26. Clinical and Laboratory Standards Institute. Reference Method 
for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Ap-
proved Standard, 3rd Edn. CLSI document M27-A3. Wayne, PA: 
Clinical and Laboratory Standards Institute; 2008. 
27. Clinical and Laboratory Standards Institute. Reference Method for 
Broth Dilution Antifungal Susceptibility Testing of Yeasts: Fourth 
Informational Supplement. CLSI document M27-S4. Wayne, PA: 
Clinical and Laboratory Standards Institute; 2012. 
28. Clinical and Laboratory Standards Institute. Reference Method for 
Broth Dilution Antifungal Susceptibility Testing of Yeasts: Third 
Informational Supplement. CLSI document M27-S3. Wayne, PA: 
Clinical and Laboratory Standards Institute; 2008. 
29. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope WW. Break-
points for antifungal agents: an update from EUCAST focusing 
on echinocandins against Candida spp. and triazoles against As-
pergillus spp. Drug Resist Updat. 2013;16:81–95. 
30. Hallen-Adams HE, Kachman SD, Kim J, Legge RM, Martínez I. 
Fungi inhabiting the healthy human gastrointestinal tract: a di-
verse and dynamic community. Fungal Ecol. 2015;15:9–17. 
31. Suhr MJ, Hallen-Adams HE. The human gut mycobiome: pit-
falls and potentials – a mycologist’s perspective. Mycologia. 
2015;107:1057–1073. 
32. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infec-
tions: epidemiology, diagnosis, and treatment. Med Mycol. 
2007;45:321–346. 
33. Pasqualottoa AC, Sukiennika TCT, Severoa LC, de Amorima CS, 
Colombo AL. An outbreak of Pichia anomala fungemia in a Bra-
zilian pediatric intensive care unit. Infect Control Hosp Epidemiol. 
2005;26:553–558. 
34. Aragão PA, Oshiro IC, Manrique EI et al. Pichia anomala out-
break in a nursery: exogenous source? Pediatr Infect Dis J. 
2001;20:843–848. 
35. Klempp-Selb B, Rimek D, Kappe R. Karyotyping of Candida al-
bicans and Candida glabrata from patients with Candida sepsis. 
Mycoses. 2000;43:159–163. 
Candida infect ion in pediatr ic  small  bowel transplant rec ip ients   9
36. Miranda LN, van der Heijden IM, Costa SF et al. Candida coloni-
zation as a source for candidemia. J Hosp Infect. 2009;72:9–16. 
37. Charles PE, Dalle F, Aube H et al. Candida spp. colonization sig-
nificance in critically ill medical patients: a prospective study. In-
tensive Care Med. 2005;31:393–400. 
38. Magill SS, Swoboda SM, Johnson EA et al. The association be-
tween anatomic site of Candida colonization, invasive candidi-
asis, and mortality in critically ill surgical patients. Diagn Micro-
biol Infect Dis. 2006;55:293–301. 
39. Odds FC, Davidson AD, Jacobsen MD et al. Candida albicans 
strain maintenance, replacement, and microvariation dem-
onstrated by multilocus sequence typing. J Clin Microbiol. 
2006;44:3647–3658. 
40. van Asbeck EC, Huang YC, Markham AN, Clemons KV, Stevens 
DA. Candida parapsilosis fungemia in neonates: genotyping re-
sults suggest healthcare workers hands as source, and review of 
published studies. Mycopathologia. 2007;164:287–293. 
41. Clark TA, Slavinski SA, Morgan J et al. Epidemiologic and mo-
lecular characterization of an outbreak of Candida parapsilosis 
bloodstream infections in a community hospital. J Clin Micro-
biol. 2004;42:4468–4472. 
42. Asmundscdóttir LR, Erlendsdóttir H, Haraldsson G, Guo H, Xu J, 
Gottfredsson M. Molecular epidemiology of candidemia: evi-
dence of clusters of smoldering nosocomial infections. Clin In-
fect Dis. 2008;47:e17–e24. 
43. Viviani MA, Cogliati M, Esposto MC, Prigitano A, Tortorano AM. 
Four-year persistence of a single Candida albicans genotype 
causing bloodstream infections in a surgical ward proven by 
multilocus sequence typing. J Clin Microbiol. 2006;44:218–221. 
44. Robles JC, Koreen L, Park S, Perlin DS. Multilocus sequence typ-
ing is a reliable alternative method to DNA fingerprinting for 
discriminating among strains of Candida albicans. J Clin Micro-
biol. 2004;42:2480–2488. 
45. Sabino R, Sampaio P, Rosado L, Stevens DA, Clemons KV, Pais 
C. New polymorphic microsatellite markers able to distinguish 
among Candida parapsilosis sensu stricto isolates. J Clin Micro-
biol. 2010;48:1677–1682. 
46. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal sus-
ceptibility survey of 2,000 blood stream Candida isolates in the 
United States. Antimicrob Agents Chemother. 2003;47:3149–3154. 
47. Prazynska M, Gospodarik E. In vitro effect of amphotericin B on 
Candida albicans, Candida glabrata, and Candida parapsilosis 
biofilm formation. Mycopathologia. 2014;177:19–27. 
48. Battaglia M, Ditonnoa P, Selvaggioa O et al. Kidney transplants 
from infected donors: our experience. Transplant Proc. 2004;36: 
491–492.  
Additional Supporting Information follows.   
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure S1. RAPD fingerprint patterns of C. albicans isolates obtained 
with primer Oligo 2. Fingerprints indicated with the same letter have equal genotypes. 
First lane 1 KB+ molecular size marker. Laboratory strain C. albicans SC5314 included 
with isolates.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure S2. RAPD fingerprint patterns of C. glabrata isolates obtained 
with primer Oligo 2. Fingerprints indicated with the same letter have equal genotypes. 
First lane 1 KB+ molecular size marker. C. glabrata NRRL Y-65 included with isolates.   
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure S3. RAPD fingerprint patterns of C. parapsilosis isolates 
obtained with primer Oligo 2. Fingerprints indicated with the same letter have equal 
genotypes. First lane 1 KB+ molecular size marker. C. parapsilosis 232 included with 
isolates.   
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure S4. RAPD fingerprint patterns of C. parapsilosis isolates 
obtained with primer OPE-04. Fingerprints indicated with the same shape have equal 
genotypes. First lane 1 KB+ molecular size marker. C. parapsilosis 232 included with 
isolates.   
 
 
 
 
 
Supplemental Table S1. MLST genotypes of the C. albicans and C. glabrata isolates 
studied. 
Candida albicans 
Sample 
Allele number MLST 
Genotype AAT1a ACC1 ADP1 MPIb SYA1 VPS13 ZWF1b 
33_I_2 156 4 4 4 204 4 4 2854 
33_B_1 156 4 4 4 204 4 4 2854 
74_B_2 35 7 6 4 4 4 239 2855 
Candida glabrata 
Sample 
Allele number MLST 
Genotype FKS LEU2 NMT1 TRP1 UGP1 URA3 
39_I_1 5 7 8 7 3 6 3 
39_B_1 5 7 8 7 3 6 3 
39_I_2 5 7 8 7 3 6 3 
47_I_3 1 2 2 1 1 1 2 
47_I_4 1 2 2 1 1 1 2 
47_I_5 1 2 2 1 1 1 2 
47_I_7 1 2 2 1 1 1 2 
47_I_9 1 2 2 1 1 1 2 
 
 
